The overall hypothesis is that insulinotropic peptides from the and somatostatin-28 [S-28], a """"""""decretin"""""""", act in concert to modulate insulin secretion on during absorption and assimilation of nutrients. Specific questions include: 1) Do """"""""ineretine"""""""" and S-28 differentially alter the periodicity and threshold of glucose-mediated insulin secretion in vitro and in vivo? 2) Do S-28 and """"""""incretins"""""""" module periodicity and kinetice of insulin secretion during nutrient absorption and is there a hierarchal order of importance amongst the putative """"""""ineretins""""""""? 3) Do elevated levels of S-28, contribute to defective insulin secretion in diabetes sellitue? The hypothesis is based on emerging information that enteric peptides including secretion, CCK, GIP and GLP-1 (7-36) potentiate the release of insulin, whereas, S-28 also from the gut, way inhibit insulin secretion. From pancreatic islet models, insulin appears to be released at varying glucose threabolds and it is plausible that """"""""incretins"""""""" and S-28 may shift the threshold and rate of insulin release by glucose and also alter the periodicity and/or amplitude of its cyclic release. Since glucone-mediated first-phase insulin secretion [equated with threshold sensitivity] is deficient in Type II diabetes mellitus, it is possible that S-28 may adversely shift the sensitivity threshold in this disorder. To address these questions, we will evaluate the effects of secretion, CCK, GIP and GLP-1 (7-36) and S-28, separately and together, on the threshold and rate of insulin release in the perfused rat pancreas and in man. Periodicity and amplitude of insulin release will also be used. To evaluate the """"""""physiologic"""""""" role of """"""""incretine"""""""" and S-28 in modulating insulin secretion in vivo, baboons will be studied before and after immunoneutralization of circulating """"""""incretins"""""""" and S-28, separately and together, during nutrient intake. To evaluate the role of S-28 on insulin secretion in defective B-cells, baboons, treated with small doses of streptozocin to induce early changes in insulin secretion, and the Goto rat model of Type II diabetes mellitus vill be examined. Insulin secretion before and after immunoneutralization with S-28 monoclonal antibodies during nutrient absorption will be tested. The results of these experiments should provide a more comprehensive view of the physiologic importance of the entero-insular axis in modulating insulin secretion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK034397-08
Application #
3232732
Study Section
Metabolism Study Section (MET)
Project Start
1984-09-01
Project End
1993-03-31
Budget Start
1991-09-01
Budget End
1993-03-31
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Elder, Deborah A; Prigeon, Ronald L; Wadwa, R Paul et al. (2006) Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 91:185-91
Quddusi, Shaista; Vahl, Torsten P; Hanson, Kevin et al. (2003) Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26:791-8
Prigeon, Ronald L; Quddusi, Shaista; Paty, Breay et al. (2003) Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-7
Ensinck, John W; Laschansky, Ellen C; Vogel, Robin E et al. (2003) Effect of ingested nutrients on the release of thrittene into the human circulation. J Clin Endocrinol Metab 88:4798-804
Ensinck, John W; Baskin, Denis G; Vahl, Torsten P et al. (2002) Thrittene, homologous with somatostatin-28((1-13)), is a novel peptide in mammalian gut and circulation. Endocrinology 143:2599-609
D'Alessio, D A; Vogel, R; Prigeon, R et al. (1996) Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-8
D'Alessio, D A; Prigeon, R L; Ensinck, J W (1995) Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44:1433-7
Burckhardt, B; Delco, F; Ensinck, J W et al. (1994) Cholecystokinin is a physiological regulator of gastric acid secretion in man. Eur J Clin Invest 24:370-6
D'Alessio, D A; Kahn, S E; Leusner, C R et al. (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-6
Hildebrand, P; Ensinck, J W; Ketterer, S et al. (1991) Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. J Clin Endocrinol Metab 72:1123-9

Showing the most recent 10 out of 15 publications